(NASDAQ: SVRA) Savara's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 64.11%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.33%.
Savara's revenue in 2025 is $0.On average, 3 Wall Street analysts forecast SVRA's revenue for 2026 to be $7,343,123,243, with the lowest SVRA revenue forecast at $2,725,877,281, and the highest SVRA revenue forecast at $12,277,668,917. On average, 3 Wall Street analysts forecast SVRA's revenue for 2027 to be $17,915,176,737, with the lowest SVRA revenue forecast at $7,240,233,892, and the highest SVRA revenue forecast at $30,105,493,285.
In 2028, SVRA is forecast to generate $25,093,090,065 in revenue, with the lowest revenue forecast at $14,827,460,395 and the highest revenue forecast at $35,358,719,735.